Russo P, Kim Y, Ravindran S, Huang W, Brennan M F
Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA.
Ann Surg Oncol. 1997 Jul-Aug;4(5):421-4. doi: 10.1007/BF02305556.
Complete resection of a retroperitoneal sarcoma often requires removal of adjacent organs. In this study we evaluated the role of nephrectomy during operation for retroperitoneal sarcoma.
Between July 1982 and July 1995, 75 of the 371 (20%) patients who underwent resection of retroperitoneal sarcoma at MSKCC underwent concommitant nephrectomy. Data concerning the reasons for nephrectomy, degree of sarcomatous renal involvement, and survival were retrospectively analyzed.
Fifty-four patients (72%) underwent nephrectomy during the initial resection, and 21 (28%) during a resection of a recurrent or persistent tumor. The most common reason for nephrectomy was total encasement by sarcoma (n = 40; 53%), followed by dense adherence of the tumor to the kidney (n = 21; 28%), and the direct invasion of the kidney by tumor (n = 2; 3%). Pathology demonstrated an absence of kidney invasion in the majority of cases (55 of 75; 73%). Renal capsular invasion was present in 11 of 75 (15%), renal parenchymal invasion in 7 of 75 (9%), and renal vein invasion in 2 of 75 (3%) of cases. There were no significant differences in survival based on degree of sarcoma involvement of the kidney, tumor grade, or whether the resection was for primary or recurrent disease. The 53 patients who underwent a complete gross resection of all tumor had a significantly improved long-term survival compared to the 20 patients who did not (50% versus 20% DFS at 5 years, respectively; p < 0.001).
Decisions for concomitant nephrectomy during resection of retroperitoneal sarcoma should be based on whether this maneuver will provide a complete resection of all gross tumor, in which case the long-term disease-free survival of 50% is comparable to the reported 5-year survival of all patients with retroperitoneal sarcoma who are completely resected.
腹膜后肉瘤的完整切除通常需要切除相邻器官。在本研究中,我们评估了肾切除术在腹膜后肉瘤手术中的作用。
1982年7月至1995年7月期间,纪念斯隆凯特琳癌症中心(MSKCC)371例接受腹膜后肉瘤切除术的患者中有75例(20%)同时接受了肾切除术。对肾切除术的原因、肉瘤累及肾脏的程度及生存情况的数据进行回顾性分析。
54例患者(72%)在初次切除时接受了肾切除术,21例(28%)在复发性或持续性肿瘤切除时接受了肾切除术。肾切除术最常见的原因是肉瘤完全包绕(n = 40;53%),其次是肿瘤与肾脏紧密粘连(n = 21;28%)以及肿瘤直接侵犯肾脏(n = 2;3%)。病理显示大多数病例(75例中的55例;73%)不存在肾脏侵犯。75例中有11例(15%)存在肾包膜侵犯,75例中有7例(9%)存在肾实质侵犯,75例中有2例(3%)存在肾静脉侵犯。基于肉瘤累及肾脏程度、肿瘤分级或切除是针对原发性还是复发性疾病,生存情况无显著差异。与20例未进行所有肿瘤完整大体切除的患者相比,53例进行了所有肿瘤完整大体切除的患者长期生存率显著提高(5年无病生存率分别为50%和20%;p < 0.001)。
腹膜后肉瘤切除术中是否同时进行肾切除术的决策应基于该操作能否实现所有大体肿瘤的完整切除,在这种情况下,50%的长期无病生存率与报道的所有接受完整切除的腹膜后肉瘤患者的5年生存率相当。